News stories about Fresenius Medical Care AG & Co. (NYSE:FMS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fresenius Medical Care AG & Co. earned a news impact score of 0.20 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.7751420105699 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Fresenius Medical Care AG & Co. (FMS) traded up 1.26% on Tuesday, hitting $46.61. 279,202 shares of the company were exchanged. Fresenius Medical Care AG & Co. has a 52 week low of $38.05 and a 52 week high of $50.22. The stock has a 50 day moving average of $47.57 and a 200 day moving average of $44.86. The company has a market capitalization of $28.61 billion, a price-to-earnings ratio of 20.35 and a beta of 0.47.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.53 by $0.05. The company had revenue of $4.47 billion during the quarter, compared to the consensus estimate of $5.20 billion. Fresenius Medical Care AG & Co. had a net margin of 7.56% and a return on equity of 10.85%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.96 EPS. Analysts predict that Fresenius Medical Care AG & Co. will post $2.33 EPS for the current fiscal year.

FMS has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Tuesday, April 25th. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday, June 28th. BidaskClub downgraded shares of Fresenius Medical Care AG & Co. from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. DZ Bank AG reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, August 7th. Finally, Royal Bank Of Canada reiterated a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, July 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $48.67.

ILLEGAL ACTIVITY NOTICE: This story was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/fresenius-medical-care-ag-co-fms-given-news-sentiment-score-of-0-20/1492351.html.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Insider Buying and Selling by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.